Effectiveness of Single Paravertebral Blockade Injection for Herniorrhaphy in Children

NCT ID: NCT02984800

Last Updated: 2022-01-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Paravertebral block (PVB) might be a technique of choice for hernia surgery due to its unilateral segmental anesthesia of the operative site, good muscle relaxation and prolonged postoperative analgesia. Despite PVB effectiveness, a continuing search for a reliable, timely and effective technique generates the investigation of a single PVB injection for children undergoing unilateral inguinal hernia repair. Two theoretical concepts were behind this investigation. First, possible spread of single PVB injection in the lumbar area over dermatomes corresponding to the inguinal hernia region in children likewise the spread over multiple adjacent segments from a single thoracic PVB injection. Second, as the inguinal region receives innervation from the ilioinguinal, iliohypogastric and genitofemoral nerves, all three arising from L1-L2 level; thus, a single PVB injection at this level could provide unilateral segmental anesthesia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be conducted prospectively, using a randomized double-blinded design. Male patients scheduled for elective unilateral herniorrhaphy will be included in the study.

Patients will be randomly allocated into two groups using the sealed envelope technique. All patients will have inhaled induction of anesthesia by facemask using oxygen and 8% sevoflurane for 2 to 4 minutes followed by placement of an IV cannula. After performing PVB injections, the sevoflurane concentration will be decreased to 0.4% to 0.8% and maintained until completion of surgery.

Then, group I will receive one PVB injection at L1-L2 and placebo PVB injections at T12-L1 and L2-L3. Group III will receive three PVB injections at T12-L1, L1-L2 and L2-L3.

Paravertebral block technique After induction of anesthesia and placement of regular anesthetic monitors, three unilateral PVBs will be performed with the child lying in the lateral position with the operative side uppermost. The needle insertion sites will be 1.5-2.0 cm lateral to the midline depending on the age and the body mass index of the child.

After aseptic preparation of the skin, a nerve stimulator (Stimuplex, B Braun AG, Melsungen, Germany) is used to identify an evoked muscular contraction appropriate for the levels. A 50 mm 21G insulated needle (Stimuplex A, B Braun AG) will be introduced perpendicular to the skin using 5 mA and 1 Hz. Then, the stimulating needle is gently manipulated to allow for adequate muscle response with a stimulating current of 0.4-0.6 mA.

In order to preserve the double-blindness of this trial, an independent nurse will prepare three syringes. Each syringe is labeled with the corresponding level of injection i.e, T12-L1, L1-L2 and L2-L3. The T12-L1 and L2-L3 syringes that will be used for group I will contain 0.45 ml placebo (0.9% normal saline) per syringe. The syringe labeled L1-L2 will contain 0.45 ml local anesthesia. On the other hand, the three syringes that will be used for group III will contain 0.15 ml local anesthesia and 0.3 ml placebo. Consequently, all patients will receive a total of 0.45 ml anesthesia and 0.9 ml placebo.

Data collection Demographic data such as age, weight and height will be collected. Non-invasive mean arterial blood pressure and heart rate will be recorded preoperatively (baseline), intraoperatively (incision of skin, dissection of hernia, traction over the sac and closure of incision) and immediately postoperatively. During the operation, any hemodynamic changes in excess of 15% from baseline values will result in a step-wise increase or decrease of the sevoflurane concentration. Intra-operative sevoflurane concentration will be recorded.

Postoperative pain assessment and analgesia As for pain assessment, the Face, Legs, Activity, Cry, Consolability (FLACC) scale will be used to measure postoperative pain (0 indicating no pain and 10 maximum possible pain).

Patients with pain score greater than 4 are given 1-2 mg/kg Tramadol hydrochloride (Tramal drops, Laboratoire Grunenthal, Aachen, Germany) A 350 mg paracetamol suppository (Tylenol CILAG SA, Schaffhouse, Switzerland) will be prescribed in pain score is less than 5.

During hospitalization trained nurses, blinded to the randomization, will collect the pain scores. Following hospital discharge, pain scores will be assessed by parents through phone calls made by the same nurses during the first postoperative day at predetermined time intervals (0h, 6h, 12h, 24h).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Reduce Pain After Herniorrhaphy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group I

Patients will receive one PVB injection at L1-L2 .

Group Type EXPERIMENTAL

Anesthesia induction

Intervention Type OTHER

All patients will have inhaled induction of anesthesia by facemask using oxygen and 8% sevoflurane for 2 to 4 minutes followed by placement of an IV cannula. After performing PVB injections, the sevoflurane concentration will be decreased to 0.4% to 0.8% and maintained until completion of surgery.

PVB injection at L1-L2

Intervention Type OTHER

Patients will receive a single PVB injection at L1-L2 and placebo PVB injections at T12-L1 and L2-L3.

Group III

Patients will receive three PVB injections at T12-L1, L1-L2 and L2-L3.

Group Type EXPERIMENTAL

Anesthesia induction

Intervention Type OTHER

All patients will have inhaled induction of anesthesia by facemask using oxygen and 8% sevoflurane for 2 to 4 minutes followed by placement of an IV cannula. After performing PVB injections, the sevoflurane concentration will be decreased to 0.4% to 0.8% and maintained until completion of surgery.

PVB injections at T12-L1, L1-L2 and L2-L3.

Intervention Type OTHER

Patients will have PVB injections at T12-L1, L1-L2 and L2-L3.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anesthesia induction

All patients will have inhaled induction of anesthesia by facemask using oxygen and 8% sevoflurane for 2 to 4 minutes followed by placement of an IV cannula. After performing PVB injections, the sevoflurane concentration will be decreased to 0.4% to 0.8% and maintained until completion of surgery.

Intervention Type OTHER

PVB injection at L1-L2

Patients will receive a single PVB injection at L1-L2 and placebo PVB injections at T12-L1 and L2-L3.

Intervention Type OTHER

PVB injections at T12-L1, L1-L2 and L2-L3.

Patients will have PVB injections at T12-L1, L1-L2 and L2-L3.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* elective unilateral herniorrhaphy

Exclusion Criteria

* history of allergic reactions to local anesthetics
* bleeding diatheses
* spinal abnormality
Minimum Eligible Age

2 Months

Maximum Eligible Age

7 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Makassed General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zoher Naja

Chairperson of Anesthesia and Pain Management Department

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Makassed General Hospital

Beirut, , Lebanon

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Lebanon

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zoher Naja, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Zoher Naja, MD

Role: primary

+9611636000 ext. 6405

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3122016

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.